Viking Therapeutics Emerges as Major Contender in Weight-Loss Drug Arena

Viking Therapeutics has captured significant market attention following the release of impressive clinical trial results for its obesity treatment candidate VK2735. The biopharmaceutical company’s latest data positions it as a serious competitor in the rapidly expanding metabolic health market.

Market observers are closely watching Viking Therapeutics’ scheduled appearances at two major November 2025 healthcare conferences: the Stifel 2025 Healthcare Conference and the Jefferies 2025 Global Healthcare Conference in London. These events are expected to provide additional momentum for the company’s visibility among investors.

The investment community has already taken notice of Viking’s progress. Roberts Glore & Co. has established a new position in the company, while William Blair analysts Read more...